Philanthropic Capture, Degraded Peer Review, and the Failure of Tobacco Harm Reduction

Philanthropic Capture, Degraded Peer Review, and the Failure of Tobacco Harm Reduction

Paper for WNC, March 2026

Roger Bate, President Center for Global Health Accountability, Fellow International Center for Law and Economics.

I. How Public Health Stopped Learning

For much of the past half-century, public health has occupied a privileged position in democratic societies. Its authority has rested not only on technical expertise but on a moral claim: that its guidance is evidence-based, politically neutral, and oriented toward population well-being. Policy disagreement is therefore often framed not as a dispute over trade-offs, but as deviation from “the science.”

That framing is increasingly difficult to sustain.

Across multiple domains — tobacco control, pandemic response, environmental health, chemical regulation, and nutrition — public-health institutions display growing resistance to correction. Policies persist long after contradictory evidence emerges. Dissent is often dismissed on presumed affiliation rather than methodological grounds. Replication is undervalued. Real-world outcomes are subordinated to modelled projections.

This paper argues that these failures are not primarily the result of corruption or bad faith. Rather, they reflect structural capture: a funding and governance architecture that aligns incentives around advocacy stability rather than empirical revision.

Tobacco harm reduction (THR) provides an unusually clear case study of how this dynamic unfolds.

II. From Philanthropy to Policy Ecosystem

Private philanthropy has long supported public health. What has changed over the past two decades is the scale and structural integration of foundation funding.

Large foundations now finance entire policy ecosystems rather than discrete projects. Funding extends simultaneously to:

• academic research centers
• advocacy NGOs
• media initiatives
• litigation campaigns
• technical advisors embedded in governments
• and participation in international norm-setting processes

Bloomberg Philanthropies’ tobacco-control initiatives illustrate this ecosystem model. Since 2007, Bloomberg has committed over $1 billion to global tobacco control (Bloomberg Philanthropies, 2023). Funding supports NGOs, university research programs, WHO Framework Convention on Tobacco Control (FCTC) implementation support, and legal advocacy organizations. This networked approach does not require explicit directives to influence outcomes. Alignment emerges through funding continuity.

As documented in broader scholarship on philanthropic governance, large foundations can shape agenda-setting indirectly by determining which research questions are fundable and which institutional narratives are amplified (Reich, 2018; McGoey, 2015). Even without formal control, sustained funding establishes intellectual path dependence.

In tobacco control, this path dependence has reinforced an abstinence-oriented framework in which nicotine use itself is treated as the central harm rather than smoking-related disease. Within such a framework, harm reduction is not merely a competing strategy — it becomes normatively destabilizing.

This is structural capture without conspiracy: incentive alignment rather than overt coercion.

III. The Degradation of Peer Review

Peer review is designed as a mechanism of quality control and adversarial testing. However, in highly politicized domains, it can function instead as boundary enforcement.

The broader scientific literature documents increasing concern regarding publication bias, replication failure, and ideological homogeneity within peer-review networks (Ioannidis, 2005; Nosek et al., 2015; Smaldino and McElreath, 2016). Replication studies are under-incentivized. Null results are less likely to be published. Citation cascades can convert tentative findings into perceived consensus (Greenberg, 2009).

In tobacco and nicotine research, several additional dynamics are present:

1. Researchers with industry affiliations are automatically subject to heightened scrutiny — often appropriately — but similar scrutiny is not always applied to advocacy-funded research.
2. Journals rely on reviewer pools drawn from the same professional networks that dominate grant funding.
3. Studies emphasizing potential youth uptake or gateway effects receive disproportionate attention relative to studies documenting cessation substitution among adults.

None of these mechanisms require explicit suppression. They operate through shared priors and reputational risk management.

Over time, this produces epistemic consolidation: a narrowing of acceptable hypotheses and methodologies. When contradictory real-world evidence emerges, it encounters a literature already aligned around precautionary framings.

Peer review remains formalized, but its corrective function weakens.

IV. The Scientific Basis for Tobacco Harm Reduction

The central toxicological distinction in tobacco science has been established for decades: the overwhelming majority of smoking-related morbidity arises from combustion products, not from nicotine itself (Royal College of Physicians, 2016; National Academies of Sciences, Engineering, and Medicine [NASEM], 2018).

Combustion generates tar, carbon monoxide, polycyclic aromatic hydrocarbons, and thousands of toxic by-products. Nicotine is addictive and not risk-free, particularly for adolescents, but it is not the primary carcinogenic agent in cigarettes.

Non-combustible nicotine products — including e-cigarettes and oral snus — dramatically reduce exposure to these toxicants. The UK’s independent evidence reviews have consistently concluded that vaping is substantially less harmful than smoking, though not risk-free (Public Health England, 2015; Office for Health Improvement and Disparities, 2022). The NASEM review similarly found substantial evidence that completely switching from combustible cigarettes to e-cigarettes reduces exposure to toxicants (NASEM, 2018).

Sweden provides the most cited population-level example. Widespread substitution of snus for cigarettes coincided with Europe’s lowest male smoking prevalence and among the lowest smoking-attributable mortality rates in the EU (Ramström, 2017; European Commission, 2023).

New Zealand explicitly incorporated vaping into its smoke-free strategy, with official communications distinguishing between combustible and non-combustible risk (Ministry of Health NZ, 2021). Smoking prevalence declined rapidly during the period in which vaping substitution increased, though multiple causal factors likely contributed.

The comparative risk framework is therefore not speculative. It is grounded in toxicology and supported by population-level observations.

The policy question is not whether vaping is harmless. It is whether, in a population where cigarette demand persists, facilitating substitution reduces net harm.

In several countries, the answer has been empirically affirmative.

V. The American Regulatory Divergence

Despite accumulating toxicological and international evidence supporting harm reduction, the United States adopted a markedly different regulatory trajectory.

The 2009 Family Smoking Prevention and Tobacco Control Act granted the U.S. Food and Drug Administration (FDA) authority over tobacco products. When e-cigarettes entered the market at scale, the FDA extended regulatory authority to them through the 2016 “Deeming Rule.” Thereafter, all non-combustible nicotine products were required to undergo premarket tobacco product application (PMTA) review.

In principle, PMTA review was intended to ensure that new products were “appropriate for the protection of public health.” In practice, the evidentiary standards, timelines, and procedural uncertainty imposed extraordinary burdens on manufacturers — particularly small and medium-sized firms.

By 2023, the FDA had received millions of PMTAs but authorized only a small fraction of products, largely limited to tobacco-flavored devices produced by major firms (FDA, 2023). Most flavored products — despite evidence that flavor variety supports adult switching (Farsalinos et al., 2013; Russell et al., 2018) — were denied authorization.

At the same time, the Centers for Disease Control and Prevention (CDC) consistently emphasized youth uptake statistics in public messaging while providing limited communication regarding relative risk differentials between combustible and non-combustible products (CDC, 2022). While concerns about adolescent nicotine exposure are legitimate, the absence of clear comparative messaging created widespread public misperception. Surveys repeatedly show that a growing proportion of U.S. adults incorrectly believe vaping to be as harmful as or more harmful than smoking (Misperceptions documented in Majeed et al., 2017; NASEM, 2018).

The combined regulatory and communications posture had predictable effects:

1. Legal supply was sharply constrained.
2. Consumer demand among adult smokers did not disappear.
3. Risk perception became distorted.

This divergence from the UK and New Zealand models was not driven by lack of scientific awareness. Rather, it reflected institutional risk aversion and advocacy alignment.

VI. Legal Contraction and Illicit Expansion

When demand persists but legal supply contracts, markets do not vanish. They reorganize.

Political economy literature on prohibition — from alcohol to narcotics to high-tax cigarettes — consistently demonstrates substitution toward illicit channels when regulatory burdens exceed consumer tolerance (Miron and Zwiebel, 1991; Chaloupka et al., 2015).

Evidence suggests a similar dynamic in U.S. vaping markets. Enforcement data from U.S. Customs and Border Protection (CBP) and the FDA document repeated seizures of unauthorized e-cigarette products entering the country (FDA, 2024). Public announcements describe millions of units detained at ports of entry.

Simultaneously, market analyses and retail surveys indicate that a substantial share of vaping products sold in U.S. convenience stores and specialty shops lack FDA authorization (Talih et al., 2022; industry retail tracking reports). Estimates of illicit market share vary, but multiple independent assessments suggest that unauthorized products account for a majority of flavored disposable sales.

This outcome should not be surprising. PMTA approval processes are lengthy and costly. Manufacturers operating outside U.S. jurisdiction can produce flavored disposables at low cost, ship them through intermediary logistics networks, and distribute through fragmented retail channels. Enforcement agencies face high monitoring costs across thousands of small retailers.

In short, regulatory design created a supply vacuum that informal networks filled.

VII. FinCEN and Trade-Based Money Laundering

The most concerning development is the intersection between illicit nicotine products and broader financial crime networks.

In 2023, the U.S. Treasury Department’s Financial Crimes Enforcement Network (FinCEN) issued an advisory highlighting trade-based money laundering (TBML) risks associated with illicit tobacco and e-cigarette trafficking (FinCEN, 2023). The advisory described how criminal organizations exploit mis-invoicing, shell companies, and transnational shipping to move unauthorized tobacco and vaping products.

FinCEN further noted that TBML schemes linked to illicit tobacco trafficking have been used by transnational criminal organizations, including those also engaged in narcotics distribution. While the advisory did not claim that vaping is a primary revenue stream for fentanyl trafficking, it did identify overlapping logistical and financial channels.

This distinction matters. The claim is not that vaping finances fentanyl at scale. The claim is that once products are pushed into illicit channels, they become embedded in broader criminal infrastructures already used for higher-margin illegal goods.

From a governance perspective, this represents a collapse of regulatory containment. Lawful firms exit; criminal logistics networks expand scope. Consumer protection erodes. Revenue that could have been regulated flows instead through opaque financial systems.

This is a foreseeable outcome when legal pathways are closed without eliminating demand.

VIII. The NGO–Journal–Regulator Feedback Loop

Why did this trajectory persist despite warning signals?

The answer lies in institutional feedback loops.

Advocacy organizations, often funded by philanthropic initiatives with explicit end goals (e.g., nicotine-free societies), produce reports emphasizing youth uptake, gateway concerns, and precautionary uncertainty. These reports cite peer-reviewed studies that often focus on behavioral correlations rather than toxicological endpoints.

Academic journals publish these studies. Citation density increases. Media outlets report on journal findings. Regulators reference both journal articles and NGO briefs when justifying restrictive measures.

This cycle generates a self-reinforcing narrative structure:

• Advocacy produces framing.
• Journals confer legitimacy.
• Media amplifies urgency.
• Regulators cite consensus.
• Advocacy claims validation.

Because each actor operates within its formal mandate, responsibility diffuses. No single institution owns outcome evaluation.

When illicit expansion becomes visible, the response is typically framed as an enforcement shortfall rather than a design flaw. Calls for stricter border controls substitute for reconsideration of regulatory thresholds.

Institutional incentives favor stability over revision.

IX. Harm Reduction as a Legitimacy Threat

Harm reduction presents a particular challenge to systems structured around abstinence-based moral clarity.

Abstinence models are rhetorically powerful: eliminate the behavior, eliminate the harm. Success is measured in declining prevalence. The metric is simple.

Harm reduction, by contrast, is comparative and probabilistic. It requires:

• Ranking relative risks.
• Accepting second-best behaviors.
• Communicating nuance.
• Tolerating imperfect substitution.

For institutions built around zero-use narratives, harm reduction appears destabilizing. It complicates funding appeals. It weakens litigation strategies premised on categorical harm. It blurs the line between regulator and market facilitator.

This does not imply malice. It implies incentive incompatibility.

When regulatory identity and advocacy mission are intertwined, policy revision becomes reputationally costly.

X. The Reappearance of Product Risk

One of the most uncomfortable consequences of restrictive nicotine policy is the reintroduction of genuine product risk through illegality.

In regulated environments such as the United Kingdom, nicotine vaping products are subject to ingredient disclosure requirements, nicotine concentration caps, notification procedures, and post-market surveillance (Office for Health Improvement and Disparities, 2022). While regulatory systems are imperfect, they create traceability and accountability.

Illicit markets provide neither.

When lawful manufacturers exit or are denied authorization, oversight shifts to informal importers and distributors. Products may be mislabelled, manufactured without quality control, or altered in transit. Consumers cannot reliably verify nicotine concentration or device safety standards.

The 2019 outbreak of e-cigarette or vaping product use-associated lung injury (EVALI) provides a cautionary illustration of this distinction. Subsequent investigation linked the outbreak primarily to vitamin E acetate in illicit THC cartridges rather than to regulated nicotine vaping products (CDC, 2020; Blount et al., 2020). However, early public messaging blurred categorical distinctions, contributing to persistent misperceptions about relative risk.

When harms emerge in illicit environments, they are often attributed to product categories rather than to regulatory context. This shields institutional design from scrutiny.

A harm-reduction framework requires distinguishing between intrinsic product risk and policy-induced risk. Failure to maintain that distinction leads to analytical error.

XI. Responsibility Without Accountability

A defining feature of contemporary public-health governance is the diffusion of responsibility.

• Philanthropic funders shape research agendas but disclaim operational control.
• NGOs influence policy framing but do not implement regulation.
• Academic journals publish research but are not accountable for policy outcomes.
• Regulators cite consensus evidence while deferring responsibility for evidence production.

Each node in the network can plausibly deny causation for downstream consequences.

This diffusion resembles what political theorists describe as “many hands” problems in administrative systems (Thompson, 1980). When authority is distributed, accountability becomes opaque.

In tobacco policy, no single actor can be said to have “caused” illicit market expansion. Yet the collective outcome is visible: constrained legal supply, distorted risk perception, and embedded criminal distribution channels.

Absent clear accountability mechanisms, institutional correction becomes unlikely.

XII. Beyond Tobacco: A Pattern of Governance Failure

The structural dynamics described here are not unique to nicotine regulation.

During the COVID-19 pandemic, epidemiological models often guided policy decisions despite high uncertainty, and dissenting interpretations were frequently marginalized (Ioannidis, 2020). Subsequent empirical reassessment of school closures and lockdown stringency has revealed complex cost–benefit trade-offs not fully acknowledged in early consensus statements (Herby et al., 2022).

In environmental health regulation, precautionary frameworks increasingly dominate even where exposure–response relationships remain uncertain, raising questions about proportionality (Sunstein, 2005).

In nutrition science, reliance on observational epidemiology has repeatedly produced shifting guidance as new analyses revise earlier conclusions (Ioannidis, 2018).

Across domains, several recurrent features appear:

1. Agenda-setting influenced by concentrated funding streams.
2. Publication systems vulnerable to confirmation bias.
3. Advocacy amplification through media channels.
4. Regulatory rigidity once policy is formalized.
5. Resistance to public revision.

These patterns do not imply bad faith. They reflect incentive structures that privilege stability over falsifiability.

The result is institutionalized certainty.

XIII. What Reform Would Require

Rhetorical commitments to “following the science” are insufficient if incentive structures reward consensus preservation.

Meaningful reform would require structural change across several dimensions.

1. Funding Pluralism

Evidence production should not be dominated by institutions financially dependent on advocacy-aligned foundations. Diversified funding sources — including support for adversarial replication and minority hypotheses — are essential to epistemic resilience (Nosek et al., 2015).

2. Peer Review Reform

Journals should incentivize replication studies, publish null findings, and reduce opacity in reviewer selection. Open peer review and pre-registration frameworks may mitigate some confirmation bias (Smaldino and McElreath, 2016).

3. Comparative Risk Communication

Public-health agencies should communicate relative risk transparently. In nicotine policy, this means distinguishing clearly between combustible and non-combustible risk rather than emphasizing absolute harm in isolation.

4. Regulatory Adaptability

Regulatory systems should incorporate adaptive review mechanisms. If illicit market share exceeds legal supply thresholds, this should trigger policy reassessment rather than escalated enforcement alone.

5. Accountability Mechanisms

Where philanthropic funding significantly shapes policy ecosystems, disclosure and governance transparency standards should be strengthened. Influence does not imply corruption — but opacity undermines legitimacy.

Without structural reform, institutional learning capacity will remain constrained.

A Final Note

The renewed scrutiny of major philanthropic actors in the wake of the Epstein document releases provides an unexpected institutional opportunity. When a foundation that occupies a central position in global health financing becomes reputationally vulnerable—even absent proven wrongdoing—it highlights how concentrated funding structures expose entire policy ecosystems to legitimacy shocks. The issue is not personal misconduct but structural dependency. Where a small number of donors finance research, advocacy, media framing, and implementation simultaneously, influence need not be directive to be consequential. Transparency becomes defensive rather than elective. In that sense, the controversy surrounding high-profile philanthropic networks may ultimately accelerate overdue reforms in disclosure, conflict-of-interest governance, and funding diversification within global health institutions. If such reforms follow, the episode will have served as a stress test that revealed systemic fragility—and forced corrective strengthening rather than further epistemic consolidation (Bate 2026).

XIV. Conclusion: Learning or Legitimacy

Public health’s historical achievements — sanitation reform, vaccination campaigns, needle exchange programs — were not products of unanimity. They emerged from iterative correction, empirical challenge, and adaptation.

Tobacco harm reduction presented a similar opportunity. Toxicological evidence, international experience, and market behavior all suggested that substitution from combustible cigarettes to non-combustible nicotine could reduce population-level harm.

In several countries, policy integrated that insight.

In the United States, institutional incentives aligned differently. Regulatory rigidity, advocacy consolidation, and degraded adversarial review contributed to a system resistant to revision. The result has been a reorganization of markets rather than elimination of demand, with unintended consequences extending into illicit trade networks.

The question is no longer whether harm reduction is controversial. It is whether public-health institutions retain the capacity to learn from empirical reality.

Legitimacy ultimately depends not on moral certainty but on corrective flexibility.

References

Bate, R (2026) “Why the Epstein Files Might Lead to Better Transparency in Global Health: Gates, WHO, and Slowing Donor Capture”, Substack

Blount, B.C., Karwowski, M.P., Shields, P.G., et al. (2020) ‘Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI’, New England Journal of Medicine, 382(8), pp. 697–705.

Bloomberg Philanthropies (2023) Tobacco Control Grants Overview. Available at: [official site].

Centers for Disease Control and Prevention (CDC) (2020) Outbreak of Lung Injury Associated with E-cigarette Use. Atlanta: CDC.

Centers for Disease Control and Prevention (CDC) (2022) National Youth Tobacco Survey. Atlanta: CDC.

Chaloupka, F.J., Yurekli, A. and Fong, G.T. (2015) ‘Tobacco taxes as a tobacco control strategy’, Tobacco Control, 21(2), pp. 172–180.

European Commission (2023) Smoking prevalence and attributable mortality in the EU. Brussels.

Farsalinos, K.E., Romagna, G., Tsiapras, D., et al. (2013) ‘Impact of flavour variability on electronic cigarette use experience’, International Journal of Environmental Research and Public Health, 10(12), pp. 7272–7282.

Financial Crimes Enforcement Network (FinCEN) (2023) Advisory on Illicit Tobacco and E-Cigarette Trafficking and Associated Trade-Based Money Laundering Risks. Washington, DC: U.S. Department of the Treasury.

Food and Drug Administration (FDA) (2023) Premarket Tobacco Product Marketing Orders. Silver Spring, MD.

Food and Drug Administration (FDA) (2024) Import Enforcement Actions on Unauthorized E-Cigarettes. Silver Spring, MD.

Greenberg, S.A. (2009) ‘How citation distortions create unfounded authority’, BMJ, 339, b2680.

Herby, J., Jonung, L. and Hanke, S. (2022) ‘A literature review and meta-analysis of the effects of lockdowns on COVID-19 mortality’, Studies in Applied Economics, Johns Hopkins University.

Ioannidis, J.P.A. (2005) ‘Why most published research findings are false’, PLoS Medicine, 2(8), e124.

Ioannidis, J.P.A. (2018) ‘The challenge of reforming nutritional epidemiologic research’, JAMA, 320(10), pp. 969–970.

Ioannidis, J.P.A. (2020) ‘A fiasco in the making?’, STAT.

Majeed, B.A., Weaver, S.R., Gregory, K.R., et al. (2017) ‘Changing perceptions of harm of e-cigarettes’, American Journal of Preventive Medicine, 52(3), pp. 331–338.

McGoey, L. (2015) No Such Thing as a Free Gift. London: Verso.

Ministry of Health New Zealand (2021) Smokefree Aotearoa 2025 Action Plan. Wellington.

Miron, J.A. and Zwiebel, J. (1991) ‘Alcohol consumption during Prohibition’, American Economic Review, 81(2), pp. 242–247.

National Academies of Sciences, Engineering, and Medicine (2018) Public Health Consequences of E-Cigarettes. Washington, DC: National Academies Press.

Nosek, B.A., Alter, G., Banks, G.C., et al. (2015) ‘Promoting an open research culture’, Science, 348(6242), pp. 1422–1425.

Office for Health Improvement and Disparities (2022) Vaping in England: Evidence Update. London: UK Department of Health.

Ramström, L. (2017) ‘The Swedish experience: snus and public health’, Harm Reduction Journal, 14(17).

Reich, R. (2018) Just Giving: Why Philanthropy Is Failing Democracy and How It Can Do Better. Princeton: Princeton University Press.

Royal College of Physicians (2016) Nicotine Without Smoke: Tobacco Harm Reduction. London: RCP.

Smaldino, P.E. and McElreath, R. (2016) ‘The natural selection of bad science’, Royal Society Open Science, 3(9), 160384.

Sunstein, C.R. (2005) Laws of Fear: Beyond the Precautionary Principle. Cambridge: Cambridge University Press.

Talih, S., Salman, R., El-Hage, R., et al. (2022) ‘Characteristics and toxicant emissions of illicit disposable e-cigarettes’, Tobacco Control, 31, pp. e105–e112.

Thompson, D.F. (1980) ‘Moral responsibility of public officials: The problem of many hands’, American Political Science Review, 74(4), pp. 905–916.